Thermo Fisher Scientific Expands its Global Biologics and Steriles Manufacturing Capabilities in China

New facility in Hangzhou, China helps pharmaceutical and biotechnology customers more quickly deliver patient therapies

[WALTHAM, Mass., (December 8, 2022)]— Thermo Fisher Scientific, the world leader in serving science, is opening a new facility in Hangzhou, China, as part of its global effort to help companies provide therapies to patients more quickly. The site can address the needs of organizations in China, as well as those outside that country, for biologics and aseptic development and manufacturing capabilities in the Asia-Pacific region.

Thermo Fisher’s new 80,000-square-meter current Good Manufacturing Practices (cGMP) facility offers integrated clinical and commercial drug substance and drug product capabilities, including process development, cell line development, biologics drug substance manufacturing and aseptic fill-finish.

“Thermo Fisher has been in China for 40 years, serving this market through its bioproduction, clinical research and pharma services businesses,” said Hann Pang, president, Thermo Fisher China. “Committed to our ‘in China, for China’ localization strategy, we are enhancing our workflow capabilities to fully support pharmaceutical and biotechnology companies in China and worldwide in helping more local innovations go global.”

The Hangzhou site is representative of the global scale of Thermo Fisher’s comprehensive end-to-end, contract development and manufacturing capabilities. With this facility and Thermo Fisher’s current capabilities in clinical packaging and logistics, the company can now offer a seamless end-to-end solution from molecule development through the accelerated delivery of critical medicines to patients.

Learn more about Large Molecule (Biologics) Development & Manfacturing.